Knight Therapeutics (TSE:GUD) Shares Down 2.5% – Should You Sell?

Knight Therapeutics Inc. (TSE:GUD) shares fell 2.5% during mid-day trading on Thursday . The stock traded as low as C$5.15 and last traded at C$5.15. 107,624 shares traded hands during trading, an increase of 36% from the average session volume of 78,912 shares. The stock had previously closed at C$5.28.

Analyst Upgrades and Downgrades

Separately, Raymond James raised shares of Knight Therapeutics to a “moderate buy” rating in a research report on Friday, November 15th.

Knight Therapeutics Price Performance

The stock has a 50 day moving average of C$5.46 and a 200-day moving average of C$5.65. The company has a debt-to-equity ratio of 7.62, a quick ratio of 1.79 and a current ratio of 3.41. The company has a market cap of C$526.29 million, a PE ratio of -26.00, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50.

Insider Activity

In other Knight Therapeutics news, Director Samira Sakhia acquired 20,000 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were purchased at an average price of C$5.15 per share, for a total transaction of C$103,000.00. Also, insider Sime Armoyan sold 300,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of C$6.13, for a total transaction of C$1,839,000.00. Corporate insiders own 45.62% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.